Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Clinical Trial Calendar
Results Date
Company Name
Ticker
Event
Indication
Outcome
Q2 2026
Mirum Pharmaceuticals Inc.
MIRM
Topline data from Phase 2b study of Volixibat (VISTAS)
Cholestatic pruritus in patients with primary sclerosing cholangitis
Q2 2026
Virax Biolabs Group Limited
VRAX
Initial data from the longitudinal assessment of the ViraxImmune FluoroSpot T cell assay's performance in detecting T cell dysfunction
Post-acute infection syndrome patients
Q2 2026
Oruka Therapeutics, Inc.
ORKA
Data from Phase 2a proof-of-concept study of ORKA-001
Moderate-to-severe psoriasis
Q2 2026
Neumora Therapeutics, Inc.
NMRA
Topline Phase 3 data of navacaprant (KOSTAL-2)
Major Depressive Disorder (MDD)
Q2 2026
Black Diamond Therapeutics
BDTX
Updated data from Phase 2 trial of BDTX-1535
Recurrent epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC)
Q2 2026
ABIVAX SA
ABVX.PA,
ABVX
Topline phase 3 44-week maintenance data of Obefazimod (ABTECT)
Moderately to severely active ulcerative colitis
Q2 2026
Neumora Therapeutics, Inc.
NMRA
Topline Phase III data of navacaprant (KOASTAL-2)
Major Depressive Disorder (MDD)
Q2 2026
Immunic, Inc
IMUX
Topline Phase 2 data of Vidofludimus calcium (ENSURE)
Multiple Sclerosis (MS)
Q2 2026
Mural Oncology plc
MURA
Final overall survival data from phase 3 trial of nemvaleukin in combination with pembrolizumab (ARTISTRY-7)
Platinum-resistant ovarian cancer
The ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s pembrolizumab in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC, according to the company. The data reported on Mar. 25, 2025.
Q2 2026
Cullinan Therapeutics, Inc.
CGEM
Initial data from Phase 1 study of CLN-978
Moderate to severe systemic lupus erythematosus (SLE)
Q2 2026
Coherus Oncology, Inc.
CHRS
Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Second-line gastric cancer
Q2 2026
Astria Therapeutics Inc
ATXS
Proof-of-concept results from Phase 1a trial of STAR-0310
Atopic dermatitis
Q2 2026
Immix Biopharma, Inc
IMMX
Final topline clinical data readout from Phase 2 trial of NXC-201 (NEXICART-2)
Relapsed/refractory AL Amyloidosis
Q2 2026
Spyre Therapeutics, Inc.
SYRE
Part A topline data from Phase 2 trial of SPY001
Moderately-to-severely active ulcerative colitis
Q2 2026
ProMIS Neurosciences, Inc.
PMN
Interim data from Phase 1b trial of PMN310 (PRECISE-AD)
Alzheimer’s Disease
Q2 2026
Apogee Therapeutics, Inc.
APGE
16-week Part B data from Phase 2 trial of APF777 (APEX)
Atopic dermatitis
Spring 2026
Whitehawk Therapeutics, Inc.
WHWK
Preclinical data of HWK-007
Lung, ovarian and endometrial cancers
Spring 2026
Whitehawk Therapeutics, Inc.
WHWK
Preclinical data of HWK-016
Gynecologic cancer, ovarian and endometrial cancers
Spring 2026
Cosmo Pharmaceuticals N.V.
COPN.SW,
CMOPF
12-month safety and tolerability data from Phase III trial of clascoterone 5% topical solution
Male androgenetic alopecia (male-pattern hair loss)
Mid 2026
Karyopharm Therapeutics Inc.
KPTI
Top-line data from Phase 3 trial of selinexor (XPORT-EC-042)
TP53 wild-type advanced or recurrent endometrial cancer
Mid 2026
Sionna Therapeutics, Inc.
SION
Topline data from Phase 1 trial of SION-451 in combination with SION-2222
Paradigm for cystic fibrosis
Mid 2026
Sionna Therapeutics, Inc.
SION
Topline data from Phase 1 trial of SION-451 in combination with SION-109.
Paradigm for cystic fibrosis
Mid 2026
AbCellera Biologics Inc
ABCL
Initial safety and efficacy data from Phase 1 trial of ABCL635
Moderate-to-severe vasomotor symptoms (VMS) associated with menopause
Positive interim reported from Phase 1 trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause on 11th May 2026.
Mid 2026
Biodexa Pharmaceuticals Plc
BDRX
Read out from Phase 2 study of eRapa
Non-muscle Invasive Bladder Cancer or NMIBC
Mid 2026
AbCellera Biologics Inc
ABCL
Data from Phase 1 trial of ABCL575
Moderate-to-severe atopic dermatitis
Buy this Content
Editors Pick
Dollar Tree Stock Up 13% On Q1 Results, Positive Outlook, Deal With DoorDash
May 28, 2026 08:13 ET
DICK'S Sporting Cuts FY26 Earnings View, Backs Adj. EPS, Sales Forecast After Q1 Growth; Stock Down
May 27, 2026 09:46 ET
French Court Rules Air France And Airbus Guilty In 2009 Plane Crash; Companies To Appeal
May 22, 2026 05:33 ET
Walmart Sees Growth In Q2, Backs FY27 Outlook After Strong Q1; Stock Down
May 21, 2026 08:33 ET